Labcorp (LH) Competitors $255.30 +4.90 (+1.96%) Closing price 05/18/2026 03:59 PM EasternExtended Trading$255.70 +0.40 (+0.16%) As of 05:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LH vs. HSIC, MEDP, AMN, BIO, and CAHShould you buy Labcorp stock or one of its competitors? MarketBeat compares Labcorp with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Labcorp include Henry Schein (HSIC), Medpace (MEDP), AMN Healthcare Services (AMN), Bio-Rad Laboratories (BIO), and Cardinal Health (CAH). These companies are all part of the "medical" sector. LH vs. HSICLH vs. MEDPLH vs. AMNLH vs. BIOLH vs. CAHHow does Labcorp compare to Henry Schein?Henry Schein (NASDAQ:HSIC) and Labcorp (NYSE:LH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation. Do insiders and institutionals hold more shares of HSIC or LH? 96.6% of Henry Schein shares are owned by institutional investors. Comparatively, 95.9% of Labcorp shares are owned by institutional investors. 0.9% of Henry Schein shares are owned by insiders. Comparatively, 0.8% of Labcorp shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend HSIC or LH? Henry Schein presently has a consensus target price of $86.83, suggesting a potential upside of 19.46%. Labcorp has a consensus target price of $308.00, suggesting a potential upside of 20.64%. Given Labcorp's stronger consensus rating and higher probable upside, analysts plainly believe Labcorp is more favorable than Henry Schein.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Henry Schein 1 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.36Labcorp 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73 Which has more risk & volatility, HSIC or LH? Henry Schein has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market. Comparatively, Labcorp has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Is HSIC or LH more profitable? Labcorp has a net margin of 6.66% compared to Henry Schein's net margin of 2.95%. Labcorp's return on equity of 16.29% beat Henry Schein's return on equity.Company Net Margins Return on Equity Return on Assets Henry Schein2.95% 15.44% 5.53% Labcorp 6.66%16.29%7.62% Does the media refer more to HSIC or LH? In the previous week, Labcorp had 5 more articles in the media than Henry Schein. MarketBeat recorded 12 mentions for Labcorp and 7 mentions for Henry Schein. Henry Schein's average media sentiment score of 1.20 beat Labcorp's score of 1.07 indicating that Henry Schein is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Henry Schein 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Labcorp 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, HSIC or LH? Labcorp has higher revenue and earnings than Henry Schein. Henry Schein is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHenry Schein$13.18B0.63$398M$3.3121.96Labcorp$13.95B1.50$876.50M$11.2922.61 SummaryLabcorp beats Henry Schein on 13 of the 16 factors compared between the two stocks.How does Labcorp compare to Medpace?Labcorp (NYSE:LH) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations. Which has more volatility and risk, LH or MEDP? Labcorp has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Medpace has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Does the media refer more to LH or MEDP? In the previous week, Medpace had 19 more articles in the media than Labcorp. MarketBeat recorded 31 mentions for Medpace and 12 mentions for Labcorp. Labcorp's average media sentiment score of 1.07 beat Medpace's score of 0.28 indicating that Labcorp is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Labcorp 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 4 Very Positive mention(s) 0 Positive mention(s) 26 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of LH or MEDP? 95.9% of Labcorp shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 0.8% of Labcorp shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts recommend LH or MEDP? Labcorp presently has a consensus target price of $308.00, suggesting a potential upside of 20.64%. Medpace has a consensus target price of $467.08, suggesting a potential upside of 11.03%. Given Labcorp's stronger consensus rating and higher possible upside, equities analysts plainly believe Labcorp is more favorable than Medpace.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Labcorp 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73Medpace 1 Sell rating(s) 10 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has preferable valuation and earnings, LH or MEDP? Labcorp has higher revenue and earnings than Medpace. Labcorp is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLabcorp$13.95B1.50$876.50M$11.2922.61Medpace$2.53B4.75$451.12M$15.9126.44 Is LH or MEDP more profitable? Medpace has a net margin of 17.19% compared to Labcorp's net margin of 6.66%. Medpace's return on equity of 120.89% beat Labcorp's return on equity.Company Net Margins Return on Equity Return on Assets Labcorp6.66% 16.29% 7.62% Medpace 17.19%120.89%24.79% SummaryMedpace beats Labcorp on 9 of the 16 factors compared between the two stocks.How does Labcorp compare to AMN Healthcare Services?AMN Healthcare Services (NYSE:AMN) and Labcorp (NYSE:LH) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends. Is AMN or LH more profitable? Labcorp has a net margin of 6.66% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Labcorp's return on equity.Company Net Margins Return on Equity Return on Assets AMN Healthcare Services-0.95% 18.01% 5.19% Labcorp 6.66%16.29%7.62% Does the media favor AMN or LH? In the previous week, Labcorp had 2 more articles in the media than AMN Healthcare Services. MarketBeat recorded 12 mentions for Labcorp and 10 mentions for AMN Healthcare Services. Labcorp's average media sentiment score of 1.07 beat AMN Healthcare Services' score of 0.27 indicating that Labcorp is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMN Healthcare Services 1 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Labcorp 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, AMN or LH? Labcorp has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAMN Healthcare Services$3.42B0.33-$95.70M-$0.87N/ALabcorp$13.95B1.50$876.50M$11.2922.61 Do analysts recommend AMN or LH? AMN Healthcare Services presently has a consensus price target of $25.29, suggesting a potential downside of 12.62%. Labcorp has a consensus price target of $308.00, suggesting a potential upside of 20.64%. Given Labcorp's stronger consensus rating and higher possible upside, analysts clearly believe Labcorp is more favorable than AMN Healthcare Services.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AMN Healthcare Services 2 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.44Labcorp 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73 Do insiders and institutionals believe in AMN or LH? 99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 95.9% of Labcorp shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by company insiders. Comparatively, 0.8% of Labcorp shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, AMN or LH? AMN Healthcare Services has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Labcorp has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Is AMN or LH a better dividend stock? AMN Healthcare Services pays an annual dividend of $1.20 per share and has a dividend yield of 4.1%. Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 1.1%. AMN Healthcare Services pays out -137.9% of its earnings in the form of a dividend. Labcorp pays out 25.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AMN Healthcare Services is clearly the better dividend stock, given its higher yield and lower payout ratio. SummaryLabcorp beats AMN Healthcare Services on 13 of the 19 factors compared between the two stocks.How does Labcorp compare to Bio-Rad Laboratories?Bio-Rad Laboratories (NYSE:BIO) and Labcorp (NYSE:LH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership. Do insiders & institutionals have more ownership in BIO or LH? 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 95.9% of Labcorp shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 0.8% of Labcorp shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate BIO or LH? Bio-Rad Laboratories currently has a consensus price target of $303.33, indicating a potential upside of 7.41%. Labcorp has a consensus price target of $308.00, indicating a potential upside of 20.64%. Given Labcorp's stronger consensus rating and higher possible upside, analysts clearly believe Labcorp is more favorable than Bio-Rad Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Rad Laboratories 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Labcorp 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73 Is BIO or LH more profitable? Labcorp has a net margin of 6.66% compared to Bio-Rad Laboratories' net margin of 6.52%. Labcorp's return on equity of 16.29% beat Bio-Rad Laboratories' return on equity.Company Net Margins Return on Equity Return on Assets Bio-Rad Laboratories6.52% 3.56% 2.49% Labcorp 6.66%16.29%7.62% Which has more volatility and risk, BIO or LH? Bio-Rad Laboratories has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Labcorp has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Does the media favor BIO or LH? In the previous week, Labcorp had 6 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 12 mentions for Labcorp and 6 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 1.09 beat Labcorp's score of 1.07 indicating that Bio-Rad Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Rad Laboratories 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Labcorp 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, BIO or LH? Labcorp has higher revenue and earnings than Bio-Rad Laboratories. Labcorp is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-Rad Laboratories$2.59B2.92$759.90M$6.0746.52Labcorp$13.95B1.50$876.50M$11.2922.61 SummaryLabcorp beats Bio-Rad Laboratories on 11 of the 16 factors compared between the two stocks.How does Labcorp compare to Cardinal Health?Labcorp (NYSE:LH) and Cardinal Health (NYSE:CAH) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment. Is LH or CAH more profitable? Labcorp has a net margin of 6.66% compared to Cardinal Health's net margin of 0.62%. Labcorp's return on equity of 16.29% beat Cardinal Health's return on equity.Company Net Margins Return on Equity Return on Assets Labcorp6.66% 16.29% 7.62% Cardinal Health 0.62%-92.61%4.46% Does the media favor LH or CAH? In the previous week, Labcorp had 6 more articles in the media than Cardinal Health. MarketBeat recorded 12 mentions for Labcorp and 6 mentions for Cardinal Health. Labcorp's average media sentiment score of 1.07 beat Cardinal Health's score of 0.58 indicating that Labcorp is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Labcorp 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardinal Health 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer LH or CAH? Labcorp currently has a consensus target price of $308.00, suggesting a potential upside of 20.64%. Cardinal Health has a consensus target price of $241.80, suggesting a potential upside of 20.96%. Given Cardinal Health's stronger consensus rating and higher probable upside, analysts clearly believe Cardinal Health is more favorable than Labcorp.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Labcorp 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73Cardinal Health 0 Sell rating(s) 2 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.94 Is LH or CAH a better dividend stock? Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 1.1%. Cardinal Health pays an annual dividend of $2.04 per share and has a dividend yield of 1.0%. Labcorp pays out 25.5% of its earnings in the form of a dividend. Cardinal Health pays out 31.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cardinal Health has raised its dividend for 29 consecutive years. Labcorp is clearly the better dividend stock, given its higher yield and lower payout ratio. Do insiders and institutionals hold more shares of LH or CAH? 95.9% of Labcorp shares are held by institutional investors. Comparatively, 87.2% of Cardinal Health shares are held by institutional investors. 0.8% of Labcorp shares are held by company insiders. Comparatively, 0.1% of Cardinal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has higher valuation & earnings, LH or CAH? Cardinal Health has higher revenue and earnings than Labcorp. Labcorp is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLabcorp$13.95B1.50$876.50M$11.2922.61Cardinal Health$222.58B0.21$1.56B$6.5430.57 Which has more volatility and risk, LH or CAH? Labcorp has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Cardinal Health has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. SummaryLabcorp beats Cardinal Health on 12 of the 20 factors compared between the two stocks. Get Labcorp News Delivered to You Automatically Sign up to receive the latest news and ratings for LH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LH vs. The Competition ExportMetricLabcorpMedical Services IndustryMedical SectorNYSE ExchangeMarket Cap$20.53B$8.17B$6.25B$22.75BDividend Yield1.15%3.06%2.80%4.13%P/E Ratio22.6122.0820.8629.86Price / Sales1.5021.46554.8924.03Price / Cash10.0912.2127.4818.80Price / Book2.464.849.694.59Net Income$876.50M$183.43M$3.56B$1.07B7 Day Performance-0.71%-1.50%-1.64%-0.98%1 Month Performance-5.73%-0.92%-2.60%-1.30%1 Year Performance2.37%0.22%30.07%22.13% Labcorp Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LHLabcorp4.7123 of 5 stars$255.30+2.0%$308.00+20.6%+2.3%$20.53B$13.95B22.6171,000HSICHenry Schein3.5817 of 5 stars$68.99-2.6%$86.83+25.9%+0.9%$8.07B$13.18B20.8425,000MEDPMedpace3.2118 of 5 stars$417.29-1.6%$467.08+11.9%+37.6%$12.11B$2.53B26.236,200AMNAMN Healthcare Services1.7174 of 5 stars$30.43+5.0%$23.50-22.8%+27.6%$1.12B$2.73BN/A2,664Analyst UpgradeHigh Trading VolumeBIOBio-Rad Laboratories1.6877 of 5 stars$243.48-4.3%$333.00+36.8%+13.7%$6.81B$2.58B40.117,450Positive NewsGap Up Related Companies and Tools Related Companies HSIC Alternatives MEDP Alternatives AMN Alternatives BIO Alternatives CAH Alternatives CHE Alternatives DGX Alternatives MCK Alternatives TMO Alternatives WST Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:LH) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Labcorp Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Labcorp With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
